Abstract
Two hundred and two patients aged 12–78 with chiefly moderate to severe asthma took part in a multicenter randomized blined group comparison of nedocromil sodium (NS) 4 mg four times daily, beclomethasone dipropionate (BD) 0.1 mg four times daily, and placebo. Patients were assessed at the start and end of a two week baseline and after three and six weeks of treatment.
Compared with placebo, both NS and BD significantly improved day-time dyspnoea and day and nighttime cough, as assessed by diary card scores. Lung function (FEV1) was significantly improved in the BD group. In the NS group there was also a significant reduction in concomitant use of inhaledβ 2-agonists. Overall opinions of efficacy by clinicians and patients were significantly in favor of both active treatments over placebo. There were no significant differences between the three treatments for peak expiratory flow rates, morning tightness or nighttime dyspnoea. Comparison between the two active treatments showed no significant differences in any of the variables.
Similar content being viewed by others
References
Editorial (1986) Bronchial asthma and the environment. Lancet ii:786–787
Charlton JRH, Velez R (1983) Some international comparisons of mortality amenable to medical intervention. Br Med J 292:295–301
Hay IFC, Higgenbottam TW (1987) Has the management of asthma improved? Lancet ii:609–611
Lal S, Malhotra S, Gribben D, Hodder D (1984) Nedocromil sodium, a new drug for the management of bronchial asthma. Thorax 39:809–812
Chatterjee PC, Fyans PG, Chatterjee SS (1986) A trial comparing nedocromil sodium (Tilade) and placebo in the management of perennial bronchial asthma. Eur J Respir Dis 69(Suppl. 147):314–316
Williams AJ, Stableforth D (1986) The addition of nedocromil sodium to maintenance therapy in the management of patients with bronchial asthma. Eur J Respir Dis 69(Suppl. 147):340–343
Wells E, Jackson CG, Harper ST, Mann J, Eady RP (1986) Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol 137:3941–3945
Moqbel R, Cromwell O, Walsh GM, Wardlaw AJ, Kurlak L, Kay AB (1988) Effect of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 43:268–276
Thorel T, Joseph M, Tsicopoulos A, Tonnel AB, Capron A (1988) Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. Int Arch Allergy Appl Immunol 85:232–237
Thorel T, Joseph M, Vorng H, Capron A (1988) Regulation of IgE-dependent antiparasite functions of rat macrophages and platelets by nedocromil sodium. Int Arch Allergy Appl Immunol 85:227–231
Mack GA, Skillings JH (1980) A Friedman-type rank test for main effects in a two-factor ANOVA. J Am Sci Assoc 75
Postma DS, Gimeno F, Van der Weile LTH, Sluiter HJ (1985) Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 67:360–368
Postma DS, De Vries K, Koeter GH, Gluiter HJ (1986) Independent influence of reversibility of airflow obstruction and non-specific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 134:276–280
James PNE, Anderson JB, Prior JG, White JP, Henry JA, Cochrane GM (1985) Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J 61:7–10
Spector SL (1985) Is your asthmatic patient really complying? Ann Allergy 55:552–556
Carrasco E, Sepulveda R (1986) The acceptability, tolerability and safety of nedocromil sodium in long-term clinical use Eur J Respir Dis 69(Suppl. 147):311–313
Lal S, Malhotra S, Gribben D, Hodder D (1986) An open assessment study of the acceptability, tolerability and safety of nedocromil sodium in long-term clinical use in patients with bronchial asthma. Eur J Respir Dis 69(Suppl. 147):136–142
Gonzalez JP, Brodgen RN (1987) Nedocromil sodium: a preliminary report of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 34:560–577
Goldstein DE, Konig P (1983) Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-adrenal axis function in children with asthma. Pediatrics 72:60–64
Yernault JC, Leclercq R, Schanderyl W, Virasoro E, De Coster A, Copinschi G (1977) The endocrinometabolic effects of beclomethasone dipropionate in asthmatic patients. Chest 71:698–702
Gaddie J, Reid LW, Skinner C, Petrie GR, Sinclair DJM, Palmer KNV (1973) Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. Lancet ii:280–281
Costello JF, Clark TJH (1974) Response of patients receiving high-dose beclomethasone dipropionate. Thorax 29:571–573
Toogood JH, Lefcoe NM, Haines DSM, Jennings B, Errington N, Baksh L, Chuang L (1977) A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 59:298–308
Nassif E, Weinberger M, Sherman B, Brown K (1987) Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 80:518–529
Hollman GA, Allen DB (1988) Overt glucocorticoid excess due to inhaled corticosteroid therapy. Pediatrics 81:452–455
Kruszynska YT, Greenstone M, Home PD, Cooke NJ (1987) Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax 42:881–884
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergmann, K.C., Bauer, C.P. & Overlack, A. A placebo-controlled blinded comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma. Lung 168 (Suppl 1), 230–239 (1990). https://doi.org/10.1007/BF02718137
Issue Date:
DOI: https://doi.org/10.1007/BF02718137